Concepts (157)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Osteocytes | 3 | 2014 | 15 | 1.060 |
Why?
|
| Femur | 11 | 2015 | 134 | 0.770 |
Why?
|
| Vitallium | 2 | 2011 | 9 | 0.640 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2011 | 44 | 0.630 |
Why?
|
| Animals | 21 | 2015 | 1349 | 0.620 |
Why?
|
| Ultrasonic Therapy | 4 | 2014 | 13 | 0.600 |
Why?
|
| Prostheses and Implants | 5 | 2014 | 71 | 0.590 |
Why?
|
| Osteogenesis | 8 | 2015 | 77 | 0.540 |
Why?
|
| Rats | 16 | 2015 | 282 | 0.520 |
Why?
|
| Transforming Growth Factor beta | 4 | 2014 | 44 | 0.520 |
Why?
|
| Rats, Sprague-Dawley | 15 | 2015 | 189 | 0.460 |
Why?
|
| Titanium | 4 | 2014 | 64 | 0.450 |
Why?
|
| Bone Morphogenetic Proteins | 3 | 2015 | 31 | 0.450 |
Why?
|
| Nickel | 1 | 2014 | 9 | 0.430 |
Why?
|
| Cobalt | 1 | 2014 | 18 | 0.430 |
Why?
|
| Bone Marrow Cells | 3 | 2010 | 33 | 0.390 |
Why?
|
| Signal Transduction | 3 | 2012 | 139 | 0.360 |
Why?
|
| Bone Regeneration | 5 | 2015 | 59 | 0.360 |
Why?
|
| NFATC Transcription Factors | 1 | 2011 | 5 | 0.340 |
Why?
|
| Calcineurin | 1 | 2011 | 6 | 0.340 |
Why?
|
| Gap Junctions | 1 | 2011 | 3 | 0.340 |
Why?
|
| Cell Communication | 1 | 2011 | 10 | 0.330 |
Why?
|
| Stromal Cells | 2 | 2010 | 21 | 0.330 |
Why?
|
| Osteoblasts | 3 | 2015 | 26 | 0.310 |
Why?
|
| Gene Expression | 2 | 2011 | 64 | 0.300 |
Why?
|
| Prosthesis Failure | 4 | 2015 | 111 | 0.300 |
Why?
|
| Inflammation | 1 | 2009 | 53 | 0.290 |
Why?
|
| Bone Remodeling | 3 | 2014 | 40 | 0.280 |
Why?
|
| Bone Morphogenetic Protein 2 | 3 | 2014 | 27 | 0.270 |
Why?
|
| Cell Line | 3 | 2014 | 72 | 0.270 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2007 | 25 | 0.250 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2014 | 110 | 0.250 |
Why?
|
| Cells, Cultured | 5 | 2011 | 167 | 0.230 |
Why?
|
| Male | 13 | 2014 | 3399 | 0.230 |
Why?
|
| Antibodies | 3 | 2015 | 17 | 0.230 |
Why?
|
| Ultrasonics | 1 | 2005 | 7 | 0.220 |
Why?
|
| Bone Resorption | 4 | 2015 | 33 | 0.220 |
Why?
|
| Bone Marrow | 3 | 2015 | 23 | 0.210 |
Why?
|
| Mice | 4 | 2015 | 465 | 0.210 |
Why?
|
| Osseointegration | 2 | 2015 | 46 | 0.200 |
Why?
|
| Osteoporosis | 2 | 2015 | 33 | 0.200 |
Why?
|
| Biomarkers | 2 | 2014 | 141 | 0.180 |
Why?
|
| Recombinant Proteins | 4 | 2014 | 64 | 0.150 |
Why?
|
| Cell Differentiation | 2 | 2010 | 46 | 0.140 |
Why?
|
| X-Ray Microtomography | 6 | 2014 | 65 | 0.140 |
Why?
|
| Microscopy, Fluorescence | 2 | 2014 | 29 | 0.130 |
Why?
|
| Models, Animal | 6 | 2014 | 62 | 0.130 |
Why?
|
| Bone and Bones | 2 | 2015 | 74 | 0.130 |
Why?
|
| Materials Testing | 3 | 2012 | 42 | 0.120 |
Why?
|
| Genetic Markers | 2 | 2015 | 13 | 0.120 |
Why?
|
| Microscopy, Phase-Contrast | 1 | 2014 | 4 | 0.110 |
Why?
|
| Molybdenum | 1 | 2014 | 5 | 0.110 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 22 | 0.110 |
Why?
|
| Cell Death | 1 | 2014 | 16 | 0.110 |
Why?
|
| Chromium | 1 | 2014 | 12 | 0.110 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2014 | 21 | 0.110 |
Why?
|
| Mice, Transgenic | 1 | 2014 | 53 | 0.110 |
Why?
|
| Glycoproteins | 1 | 2014 | 21 | 0.110 |
Why?
|
| Bone Matrix | 1 | 2014 | 13 | 0.100 |
Why?
|
| Gene Expression Regulation | 1 | 2014 | 66 | 0.100 |
Why?
|
| Osteolysis | 1 | 2014 | 46 | 0.100 |
Why?
|
| Polyethylene | 1 | 2012 | 20 | 0.090 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2012 | 3 | 0.090 |
Why?
|
| Adult Stem Cells | 1 | 2012 | 3 | 0.090 |
Why?
|
| Heterocyclic Compounds | 1 | 2012 | 5 | 0.090 |
Why?
|
| Prosthesis Implantation | 1 | 2012 | 11 | 0.090 |
Why?
|
| Cell Movement | 1 | 2012 | 24 | 0.090 |
Why?
|
| Antibodies, Monoclonal | 1 | 2012 | 30 | 0.090 |
Why?
|
| Disease Models, Animal | 4 | 2015 | 222 | 0.090 |
Why?
|
| Fracture Healing | 1 | 2012 | 16 | 0.090 |
Why?
|
| Calcineurin Inhibitors | 1 | 2011 | 8 | 0.090 |
Why?
|
| Cell Nucleus | 1 | 2011 | 18 | 0.080 |
Why?
|
| Enzyme Activation | 1 | 2011 | 36 | 0.080 |
Why?
|
| Enzyme Inhibitors | 1 | 2011 | 51 | 0.080 |
Why?
|
| Radiation Dosage | 1 | 2011 | 15 | 0.080 |
Why?
|
| Gene Expression Profiling | 1 | 2010 | 34 | 0.080 |
Why?
|
| Arthroplasty, Replacement, Hip | 1 | 2011 | 135 | 0.070 |
Why?
|
| Interleukin-6 | 1 | 2009 | 29 | 0.070 |
Why?
|
| Apoptosis | 1 | 2009 | 65 | 0.070 |
Why?
|
| Dactinomycin | 1 | 2007 | 3 | 0.060 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2007 | 3 | 0.060 |
Why?
|
| Growth Differentiation Factor 5 | 1 | 2007 | 3 | 0.060 |
Why?
|
| Cycloheximide | 1 | 2007 | 4 | 0.060 |
Why?
|
| Guided Tissue Regeneration | 1 | 2006 | 3 | 0.060 |
Why?
|
| Biomimetic Materials | 1 | 2006 | 5 | 0.060 |
Why?
|
| Femoral Fractures | 1 | 2006 | 11 | 0.060 |
Why?
|
| Extracellular Matrix | 1 | 2006 | 14 | 0.060 |
Why?
|
| Up-Regulation | 1 | 2007 | 54 | 0.060 |
Why?
|
| Female | 4 | 2015 | 3346 | 0.060 |
Why?
|
| Osteonectin | 1 | 2005 | 4 | 0.060 |
Why?
|
| Genes, jun | 1 | 2005 | 4 | 0.060 |
Why?
|
| Immediate-Early Proteins | 1 | 2005 | 4 | 0.060 |
Why?
|
| Early Growth Response Protein 1 | 1 | 2005 | 4 | 0.060 |
Why?
|
| Osteopontin | 1 | 2005 | 4 | 0.060 |
Why?
|
| Sialoglycoproteins | 1 | 2005 | 6 | 0.060 |
Why?
|
| Genes, myc | 1 | 2005 | 5 | 0.060 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2005 | 8 | 0.060 |
Why?
|
| Cyclooxygenase 2 | 1 | 2005 | 12 | 0.060 |
Why?
|
| Repressor Proteins | 1 | 2005 | 7 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 37 | 0.060 |
Why?
|
| Transcription Factors | 1 | 2005 | 61 | 0.060 |
Why?
|
| DNA-Binding Proteins | 1 | 2005 | 94 | 0.050 |
Why?
|
| Ovariectomy | 2 | 2015 | 14 | 0.050 |
Why?
|
| Regeneration | 2 | 2015 | 10 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 2 | 2015 | 122 | 0.050 |
Why?
|
| Humans | 2 | 2012 | 5837 | 0.050 |
Why?
|
| Random Allocation | 2 | 2012 | 33 | 0.050 |
Why?
|
| Wnt Proteins | 2 | 2012 | 9 | 0.040 |
Why?
|
| Bone Density | 2 | 2014 | 90 | 0.040 |
Why?
|
| Mice, Inbred Strains | 1 | 2015 | 9 | 0.030 |
Why?
|
| Mice, Inbred C3H | 1 | 2015 | 8 | 0.030 |
Why?
|
| Species Specificity | 1 | 2015 | 16 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2015 | 23 | 0.030 |
Why?
|
| Phenotype | 1 | 2015 | 96 | 0.030 |
Why?
|
| Diaphyses | 1 | 2014 | 5 | 0.030 |
Why?
|
| Organ Specificity | 1 | 2014 | 7 | 0.030 |
Why?
|
| Macaca fascicularis | 1 | 2014 | 10 | 0.030 |
Why?
|
| Humerus | 1 | 2014 | 24 | 0.030 |
Why?
|
| Tibia | 1 | 2014 | 60 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 163 | 0.020 |
Why?
|
| Lumbar Vertebrae | 1 | 2014 | 77 | 0.020 |
Why?
|
| Periosteum | 1 | 2012 | 4 | 0.020 |
Why?
|
| Tensile Strength | 1 | 2012 | 7 | 0.020 |
Why?
|
| Colony-Forming Units Assay | 1 | 2012 | 4 | 0.020 |
Why?
|
| Benzylamines | 1 | 2012 | 11 | 0.020 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2012 | 6 | 0.020 |
Why?
|
| Receptors, CXCR4 | 1 | 2012 | 11 | 0.020 |
Why?
|
| Reference Values | 1 | 2012 | 45 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2012 | 36 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2012 | 32 | 0.020 |
Why?
|
| Radiography | 1 | 2012 | 129 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2012 | 43 | 0.020 |
Why?
|
| Endothelial Cells | 1 | 2012 | 16 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2012 | 94 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2012 | 112 | 0.020 |
Why?
|
| Biomechanical Phenomena | 1 | 2012 | 156 | 0.020 |
Why?
|
| Collagen | 1 | 2012 | 31 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2012 | 150 | 0.020 |
Why?
|
| Time Factors | 1 | 2012 | 374 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2010 | 3 | 0.020 |
Why?
|
| Bayes Theorem | 1 | 2010 | 7 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2010 | 18 | 0.020 |
Why?
|
| Matrix Metalloproteinases | 1 | 2010 | 9 | 0.020 |
Why?
|
| Transducers | 1 | 2010 | 5 | 0.020 |
Why?
|
| Alkaline Phosphatase | 1 | 2010 | 11 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2010 | 28 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2010 | 35 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2010 | 48 | 0.020 |
Why?
|
| Equipment Design | 1 | 2010 | 38 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2012 | 601 | 0.020 |
Why?
|
| Rats, Long-Evans | 1 | 2009 | 4 | 0.020 |
Why?
|
| Ossification, Heterotopic | 1 | 2009 | 15 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2009 | 51 | 0.020 |
Why?
|
| Biomimetics | 1 | 2006 | 5 | 0.020 |
Why?
|
| Matrix Metalloproteinase 13 | 1 | 2006 | 5 | 0.020 |
Why?
|
| Oligopeptides | 1 | 2006 | 10 | 0.020 |
Why?
|
| Tissue Engineering | 1 | 2006 | 10 | 0.020 |
Why?
|